# Lynda A. Szczech

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lynda-a-szczech/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,193 |
| Field | Dialysis and Renal Disease Management |
| h-index | 57 |
| i10-index | 115 |
| OpenAlex ID | https://openalex.org/A5043911240 |
| Works | 230 |

## Researcher papers

- [Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease](https://scholariq.org/papers/correction-of-anemia-with-epoetin-alfa-in-chronic-kidney-disease/)
- [Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis](https://scholariq.org/papers/roxadustat-treatment-for-anemia-in-patients-undergoing-long-term-dialysis/)
- [Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis](https://scholariq.org/papers/roxadustat-for-anemia-in-patients-with-kidney-disease-not-receiving-dialysis/)
- [Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes](https://scholariq.org/papers/secondary-analysis-of-the-choir-trial-epoetin-dose-and-achieved-hemoglobin/)
- [Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD](https://scholariq.org/papers/oral-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitor-roxadustat-fg-4592/)
- [Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study](https://scholariq.org/papers/roxadustat-fg-4592-versus-epoetin-alfa-for-anemia-in-patients-receiving/)
- [Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients](https://scholariq.org/papers/association-of-intradialytic-blood-pressure-changes-with-hospitalization-and/)
- [Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China](https://scholariq.org/papers/phase-2-studies-of-oral-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitor-fg/)
- [Intradialytic Blood Volume Monitoring in Ambulatory Hemodialysis Patients](https://scholariq.org/papers/intradialytic-blood-volume-monitoring-in-ambulatory-hemodialysis-patients/)

## Researcher topics

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)
- [HIV-related health complications and treatments](https://scholariq.org/topics/hiv-related-health-complications-and-treatments/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.